key: cord-0681100-f60z1pzk
authors: Leung, C. H.; Gibbs, Mar'ia E.; Par'e, Philip E.
title: The Impact of Vaccine Hesitancy on Epidemic Spreading
date: 2021-09-28
journal: nan
DOI: nan
sha: 9304899f6b5041f2d046022b7a99803fba4cbd90
doc_id: 681100
cord_uid: f60z1pzk

The COVID-19 pandemic has devastated the world in an unprecedented way, causing enormous loss of life. Time and again, public health authorities have urged people to become vaccinated to protect themselves and mitigate the spread of the disease. However, vaccine hesitancy has stalled vaccination levels in the United States. This study explores the effect of vaccine hesitancy on the spread of disease by introducing an SIRS-V$_kappa$ model, with compartments of susceptible (S), infected (I), recovered (R), and vaccinated (V). We leverage the concept of carrying capacity to account for vaccine hesitancy by defining a vaccine confidence level $kappa$, which is the maximum number of people that will become vaccinated during the course of a disease. The inverse of vaccine confidence is vaccine hesitance, $(frac{1}{kappa})$. We explore the equilibria of the SIRS-V$_kappa$ model and their stability, and illustrate the impact of vaccine hesitance on epidemic spread analytically and via simulations.

especially apparent regarding the reception of the COVID-19 vaccine. As of September 11, 2021, 53% of Americans have been fully vaccinated against COVID-19, with an additional 9.2% partially vaccinated [11] . However, these levels are lower than those predicted by a February 2021 survey by Pew Research Center. According to the survey, 69% of Americans reported they would probably, definitely, or had already been at least partially vaccinated [15] . In fact, the number of vaccines administered daily in the U.S. in September 2021 is less than half of those administered daily in mid-April 2021 [11] .

There have been dozens of studies on COVID-19 vaccine hesitance around the world [16] [17] [18] . There are also studies on how vaccination levels affect the dynamics of disease spread. Pires and Crokidakis explore the effect of vaccine opinions in the spread of a disease [19] . Similarly, [20] considers the dynamics when opinions are continuous. However, to the best of the authors' knowledge, the correlation between a maximum vaccination capacity κ and the equilibria of system dynamics [21] has not yet been established. This work analytically illustrates the effect of κ on the dynamics of COVID-19 spread. Specifically, κ is shown to determine the endemic and disease-free equilibria of the SIRS-V κ system.

In this paper, we take an SIRS model and add a vaccinated compartment with a vaccine confidence κ as the upper-bound of vaccination level. The result is an SIRS-V κ model: susceptible (S), infected (I), recovered (R), vaccinated (V). Figure 1 gives a graphical representation of the compartmental flow.

Definition II.1 (Vaccine Hesitance). We define the vaccine hesitance as κ −1 , where κ is the vaccine confidence.

Each compartment in the grouped SIRS-V κ model is a scalar between 0 and 1 modeling the fraction of the population in each epidemic compartment at time t. The following are the equations describing the flow from one compartment to another in the group SIRS-V κ model:Ṡ

The parameters are defined as follows:

• β is the frequency-dependent transmission rate • γ is the recovery rate • ρ is the rate of vaccination roll-out • κ is the vaccine confidence of the population

• ω is the rate of waning natural immunity.

All of the above parameters are defined in the range of (0, ∞).

Assumption 1 (Frequency dependent and population preserving system). We assume S(t 0 ),

where κ := min{1, κ}, and S(t 0 ) + I(t 0 ) + R(t 0 ) + V (t 0 ) = 1 ∀i ∈ {1, ..., n}. Furthermore, all parameters of the system are strictly positive. Lemma II.1 (Permissible range of V ). Let Assumption 1 hold, then 0 ≤ V (t) ≤ κ ∀t ≥ t 0 , ∀i ∈ {1, ..., n}.

Proof. Suppose Assumption 1 holds, we first note thatV (t 0 ) = ρ(S(t 0 ) + R(t 0 )) ≥ 0 when V (t 0 ) = 0. Furthermore,

The following lemma shows that the bounds on the initial state apply to all states for all t ≥ t 0 . Proof. We first observe thatṠ(t) +İ(t) +Ṙ(t) +V (t) = 0 ∀t ≥ 0 by summing over (1a)-(1d), then by taking the integration: To show that S(t), I(t), R(t), V (t) ∈ [0, 1] ∀t ≥ 0, we rewrite the state vector as z(t) ∈ R 4 , then we note that for any j ∈ {1, . . . , 4},ż j = −z j f j (z k =j )+g j (z) where f j (z k =j ), g j (z) ≥ 0 ∀z ≥ 0, also z k =j is the state vector z without its j th entry.

This applies toż j =V also, as we have demonstrated in Lemma II.1. Then, we observe that lim zj ↓0żj (t) = g j (z) ≥ 0 ∀z ≥ 0.

Therefore, z(t) ≥ 0 when z(t 0 ) ≥ 0. Then z j (t) ≤ 1 follows directly from z j (t) ≥ 0 and S(t) + I(t) + R(t) + V (t) = 1.

We denote the set of admissible states of (1) by S = {(S(t), I(t), R(t), V (t)) :

This section will lay down the existence and uniqueness of the two equilibria of the SIRS-V κ model and their stability conditions. We denote an equilibrium of the SIRS-V κ model as (S * , I * , R * , V * ) where S * , I * , R * , and V * are the steady-state values of (1) as t → ∞.

Definition III.1 (Disease-Free Equilibrium). A disease-free equilibrium (DFE) is an equilibrium with the steady-state infected

Similarly, we define the endemic equilibrium as follows:

Definition III.2 (Endemic Equilibrium Point). An endemic equilibrium point (EEP) is an equilibrium with the steady-state Proof. Assume, by way of contradiction, that S (e) = 0, thenṠ (e) = −γI = 0, which contradicts the definition of EEP.

Therefore, S (e) > 0. A similar argument can be made by substituting R (e) = 0 into (1c) to get R (e) > 0. Therefore, from (1d),

and the only way for the R.H.S. to equal zero is if V (e) = κ. Notice that (2) cannot be satisfied when κ ≥ 1, and therefore, EEP only exists when κ < 1, concluding the proof.

Lastly, we reiterate the definition of the basic reproduction number through the next generation matrix method [22] , [23] :

is the function governing the rate of appearance, g i (z) is the function governing the rate of transferring into other compartments, and i ∈ {1, . . . , m} for m infected compartments out of n total compartments. Let

. . , m}, then F V −1 is the next generation matrix, and its spectral radius σ(F V −1 ) is the basic reproduction number R 0 of the system. z 0 is the initial condition where full susceptibility of population is assumed (S(t 0 ) ≈ 1). The effective reproduction number is defined as R t := S(t)R 0 .

The ij th entry of F V −1 is the expected number of secondary cases in the i th compartment produced by an infected individual in the j th compartment [24] . In the case of a single infected compartment, it is simply the average number of secondary infected cases introduced by one infected individual.

Proposition 1. The basic reproduction number R 0 of (1) is β γ , and the effective reproduction number R t is upper bounded

Proof. From (1b), f (I) = βSI, g(I) = γI. By computing the Jacobians, we get F = ∂βSI(t0)

Notice that we use the word uniqueness in the following text not to refer to the uniqueness of the set of all equilibria of (1) but of a particular class of equilibria, i.e. the DSF and EEP are sets of cardinality at most one. As we will see in the following, the EEP could be an empty set under certain conditions. Proposition 2 (Existence and uniqueness of DFE). There always exists a unique disease-free equilibrium (S (d) ,

Proof. By the definition of a disease-free equilibrium and from (1b), we know the j th DFE is characterized by I (dj ) = 0, anḋ

which implies either:

In the first case (3), we can substitute V (d1) into (1d) and solve for S (d1) + R (d1) = 0. By Assumption 1 and Lemma II.2, κ S (d2) , which leads to two subcases:

In the first subcase (4a), since I (d21) = 0 by the definition of the DFE and R (d21) = 0 by (4) Remark. Note that κ ceases to act as an upper bound on the vaccination state while still affecting the effective rate of vaccination ρ 1 − V κ when κ is greater than 1. Moreover, ρ 1 − V κ → ρ as κ → ∞.

Proposition 3 (Uniqueness of EEP). The endemic equilibrium point of (1):

S (e) , I (e) , R (e) , V (e) = γ β ,

Proof. If an endemic equilibrium exists, by Definition III.2, I (e) > 0. Applying this fact and setting (1b) to zero gives S (e) = γ β . Therefore, the result from Lemma III.1, with n = 1, implies V (e) = κ. By substituting V (e) = κ into (1c), we will have I (e) R (e) = ω γ . To solve for I (e) and R (e) , recall the global preservation of population result in Lemma II.2, we have I (e) + R (e) = 1 − κ − γ β . We can combine this equation with I (e) R (e) = ω γ , then solving for the system of two equations with two unknowns gives us the desired result. Therefore, we have shown the uniqueness of permissible EEP under Assumption 1.

Notice that since I * can either be 0 or (0, 1], the DFE and the EEP are the only two possible admissible equilibria of (1) under Assumption 1.

Proof. From Assumption 1 and Lemma II.2, the EEP in Proposition 3 exists if and only if the range of parameters satisfy the four inequality:

The first and forth constraints are absorbed by Assumption 1 and the second constraint. The second and third constraints can be reduced to 0 < 1 − κ − γ/β, which is equivalent to κ < 1 − γ/β and (1 − κ) β γ > 1. Theorem 1 (DFE GAS Conditions). The DFE of (1) is globally asymptotically stable (GAS) if and only if (1 − κ) β γ ≤ 1.

Proof. Our goal is to show by exhaustion of cases that all the states in S are either the DFE or will approach the DFE as t → ∞ under the condition (1 − κ) β γ ≤ 1. Fig. 2 visualizes the simplex of states, i.e. the range of admissible states S, of which we want to show GAS around the DFE. Hence, every admissible state in (1) which satisfies S(t) + R(t) = 0 will haveṘ(t) > 0, hence evolving to another state such that S(t) + R(t) = 0. In other words, states on the IV edge in Fig. 2 are not stable and will move toward vertex R as time unfolds. The only state on IV which violates this tendency of evolving towards R is the vertex V , which is already the DFE if it lies within S. For every state that satisfies (S(t) + R(t) > 0 ∧ V (t) < κ),

by substituting S(t) + R(t) > 0 into (1d). Therefore, every state with V (t) < κ will satisfy V (t) = κ as t → ∞ or it is already the DFE.

If (I(t) = R(t) = 0 ∧ V (t) = κ), then S(t) = 1 − κ by Assumption 1 and Lemma II.2, which state that S(t) + I(t) +

where (6) holds because the condition (1 − κ) β γ ≤ 1 is equivalent to γ β ≥ 1 − κ and (7) holds because I(t) + R(t) > 0. Therefore, from (1b) and (7), we haveİ

where equality holds only if I(t) > 0. Therefore, every state which satisfies V (t) = κ will satisfy (V (t) = κ ∧ I(t) = 0) as t → ∞ or it is already the DFE.

Lastly, for any state that satisfies (V (t) = κ ∧ I(t) = 0 ∧ R(t) > 0), from (1c), we havė

Thus, every state that satisfies (V (t) = κ ∧ I(t) = 0 ∧ R(t) > 0) will satisfy (V (t) = κ ∧ I(t) = 0 ∧ R(t) = 0) as t → ∞ or it is already the DFE. Therefore, the DFE is GAS if

then there exists an EEP in S by Lemma III.2, which concludes the other direction of the proof.

Referring to the points in Fig. 2 , (1 − κ) β γ ≤ 1 is achieved when the plane ABD slides up or DF G slides back, such that the segment P Q vanishes. One can show that all states above the ABC plane haveİ > 1 and belowİ < 1. An intuitive way to interpret Theorem 1 is that when ABC is strictly above DF G, all states are pushed away from I and pulled toward V , until they reach the DFE.

Remark. Notice that the necessary and sufficient GAS condition of the disease-free equilibrium is not R 0 < 1 for the SIRS-V κ model, because the basic reproduction number only guarantees sufficient local asymptotic stability when it is less than one. Therefore, it might at times over/under-estimate the threshold condition of the spread process. 

In this section, we investigate the impact of the vaccine confidence κ on the behavior of the SIRS-V κ model. Fig. 3 compares the trajectories of the vaccination level V (t) with different values of κ, ranging from 0.1 to ∞. Note that, consistent with the analysis results, κ slows the rate of convergence and, if κ < 1, can lower the limit of V (t). Since β γ = 2 in this case, κ = 0.5 barely satisfies the condition for GAS in Theorem 1 to reach the DFE as time goes to infinity. We also notice that κ slows the rate of convergence of I(t) when comparing the cases κ = (0.5, 0.6, 1.2, ∞). 5 compares I(t) and R(t) between the SIRS, SIRSV, and SIRS-V κ models. Notice the key difference between the three models is that SIRSV and SIRS-V κ has ρ > 0 while SIRS has ρ = 0, and SIRSV κ has κ = 0.8 < ∞ while SIRSV assumes κ → ∞. In this particular setup, both the SIRSV and SIRSV κ models reach the DFE before t = 40, while the SIRS model settles at the EEP. Furthermore, we observe a higher infection peak with slower peak time in the SIRS-Vκ model.

To investigate how the vaccine confidence affects the maximum peak infection value and time, we plot the maximum peak Fig. 6 . Note that the maximum peak infection value decreases monotonically with κ. On the other hand, the peak infection time reaches its maximum when κ = 0.2 before decaying, which is not expected and will need further investigation. Fig. 7 plots the earliest time when I(t) < 0.001 with respect to different (1 − κ) β γ through varying κ. We use the condition I(t) < 0.001 as a way to investigate the asymptotic behavior of the system under different parameter settings. The program returns −10 if I(t) fails to converge close enough to 0 before t = 100. The sharp drop at (1 − κ) β γ ≈ 1 aligns with our finding in Lemma III.2 and Theorem 1 that the DFE ceases to be GAS when (1 − κ) β γ is larger than 1. Note that the drop occurs slightly before 1 because we do not allow t > 100, which is much smaller than asymptotic time. Finally, all the simulations indicate that the EEP has a large region of convergence as long as it exists in S. More investigation is required to firmly conclude these findings analytically.

In this paper, we have proposed an SIRS-V κ model, where κ is the vaccine confidence level. We have proved the existence of unique endemic and disease-free states, both of which depend on κ. Furthermore, κ acts as an important component in determining the necessary and sufficient condition of the global asymptotic stability, namely (1 − κ) β γ ≤ 1, of the diseasefree equilibrium. From the perspective of control, manipulating the transmission rate β, recovery rate γ, and the vaccine confidence κ are equally viable ways of mitigating epidemic spread. From the disease modeling perspective, we have shown through analytical and numerical methods that ignoring vaccine confidence in the model will introduce significant biases when determining the system's stability condition, maximum peak infection time, and its threshold behaviors. The dependence of COVID-19 prevalence on vaccine hesitance should encourage Americans to become vaccinated if they have not done so already.

For future work, we are interested in extending our findings from the scalar case to the networked case to further inspect the impact of varying vaccine confidence across different geographic/demographic populations. Moreover, we also would like to provide analysis on the region of convergence of EEP and DFE when (1 − κ) β γ > 1, and the effect of vaccine confidence on the maximum peaking time of I(t).

Modeling Infectious Diseases in Humans and Animals

Daniel Bernoulli's epidemiological model revisited

Contributions to the mathematical theory of epidemics. ii.-the problem of endemicity

Modeling, estimation, and analysis of epidemics over networks: An overview

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy

An inquiry into the causes and effects of the Variolae Vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox. printed, for the author

Vaccines in historic evolution and perspective: A narrative of vaccine discoveries

The eradication of smallpox-an overview of the past, present, and future

Immunization coverage

An interactive web-based dashboard to track COVID-19 in real time

A global database of COVID-19 vaccinations

Different COVID-19 vaccines

Vaccine hesitancy: An overview

MacDonald and the SAGE Working Group on Vaccine Hesitancy

Growing share of Americans say they plan to get a COVID-19 vaccine-or already have

COVID-19 vaccine hesitancy in Poland-multifactorial impact trajectories

Prevalence and factors associated with COVID-19 vaccine hesitancy in Maranhão, Brazil

COVID-19 vaccine hesitancy-a scoping review of literature in high-income countries

Dynamics of epidemic spreading with vaccination: Impact of social pressure and engagement

Sudden transitions in coupled opinion and epidemic dynamics with vaccination

Carrying capacity: a confusing concept

On the definition and the computation of the basic reproduction ratio R 0 in models for infectious diseases in heterogeneous populations

Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission

Reproduction numbers of infectious disease models